Companies: 10,795·Total market cap: $144.5T
Novartis AG

Novartis AG

NVSNYSEHealthcare● Active
$149.16
+$0.76(+0.51%)
Market Cap$284.6B
P/E Ratio—
52W High$170.46
52W Low$112.34
Cash on HandFinancialsRevenue

Novartis AG (NVS) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

NVS · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$11.59B▼ -13.2% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$11.44B
cashAndCashEquivalents
Short-Term Investments
$155.0M
shortTermInvestments
YoY Change vs Prior Year
-13.2%
vs prior fiscal year
Latest Quarter
$6.98B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$11.59BCash on Hand
Total Debt$37.03BTotal Debt
Net Cash / Net Debt−$25.44BNet Debt Position
Cash vs Debt Ratio
Cash 24%Debt 76%

Novartis AG carries a net debt position of $25.44B. Total debt ($37.03B) exceeds cash on hand ($11.59B). Novartis AG cash vs debt ratio: 24% cash / 76% debt.

Net Cash = Cash & ST Investments − Total Debt$11.59B − $37.03B = −$25.44B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
NVS annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$11.59B-13.2%
Dec 31, 2024$13.35B-4.4%
Dec 31, 2023$13.96B-25.0%
Dec 31, 2022$18.61B-33.8%
Dec 31, 2021$28.11B+143.1%
NVS cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Novartis AG
Novartis AGYOU
NVS
$11.59B4.1%
#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Novartis AG (NVS) cash on hand as of December 31, 2025 is $11.59B, comprising $11.44B in cash and cash equivalents (CCE) plus $155.0M in short-term investments — reported as Novartis AG cash and short-term investments on the balance sheet (10-K filing). Also referred to as Novartis AG cash reserves or cash position.

Novartis AG annual cash on hand history shows decreased -13.2% in 2025: decreased -13.2% in 2025. Novartis AG cash reserves in 2025 reflect the company's capital allocation strategy.

Novartis AG carries total debt of $37.03B against cash of $11.59B, resulting in a net debt position of -$25.44B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

NVS cash on hand · 5 questions

As of December 31, 2025, Novartis AG (NVS) has $11.59B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $11.44B in cash and cash equivalents (CCE) plus $155,000,000 in short-term investments. Latest quarter (March 31, 2026): $6.98B. Data sourced from the annual 10-K filing via FMP.

NVS cash on handNVS cash reservesNVS cash 2025how much cash does NVS have

▸ Source: FMP /balance-sheet-statement · US GAAP · Novartis AG · Novartis AG SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025